Cardiometabolic Disease Market Trends and Forecast
The future of the global cardiometabolic disease market looks promising with opportunities in the clinic and hospital markets. The global cardiometabolic disease market is expected to grow with a CAGR of 6.1% from 2024 to 2030. The major drivers for this market are global increase in the prevalence of cardiometabolic diseases such as diabetes, hypertension, dyslipidemia, and obesity, advancements in medical technology and therapeutics, and rising healthcare expenditure, particularly in developed and emerging markets.
• Lucintel forecasts that chronic/congestive heart failure is expected to witness the highest growth over the forecast period.
• Within this market, hospitals is expected to witness the higher growth.
• North America will remain the largest region over the forecast period.
Country Wise Outlook for the Cardiometabolic Disease Market
• United States: Amgen announced FDA approval for its new cardiovascular drug, targeting reduction in cardiovascular events. Government initiatives support reimbursement for innovative therapies to manage cardiometabolic conditions.
• Germany: Bayer launched a digital health platform to monitor and manage diabetes and cardiovascular diseases, aiming to improve patient outcomes. Government targets include reducing diabetes prevalence by promoting preventive healthcare.
• China: Sinopharm initiated clinical trials for a novel insulin therapy for diabetes management. Government targets include expanding access to affordable treatments and improving diabetes care infrastructure.
• India: Dr. ReddyÄX%$%Xs Laboratories introduced a generic version of a popular cardiovascular medication, aiming to improve affordability and access. Government focuses on reducing hypertension prevalence through public health campaigns and healthcare reforms.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Cardiometabolic Disease Market by Segment
The study includes a forecast for the global cardiometabolic disease market by type, treatment, end use, distribution channel, and region.
Cardiometabolic Disease Market by Type [Value from 2018 to 2030]:
• Chronic/Congestive Heart Failure
• Hypertension
• Type 2 Diabetes
• Obesity
Cardiometabolic Disease Market by Treatment [Value from 2018 to 2030]:
• ACE Inhibitors
• Diuretics
• Glucophage
• Liposuction
• Others
Cardiometabolic Disease Market by End Use [Value from 2018 to 2030]:
• Clinics
• Hospitals
• Others
Cardiometabolic Disease Market by Distribution Channel [Value from 2018 to 2030]:
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
Cardiometabolic Disease Market by Region [Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Cardiometabolic Disease Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cardiometabolic disease companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cardiometabolic disease companies profiled in this report include-
• Cardax
• Novartis AG
• Novo Nordisk A/S
• Eli Lilly and Company
• Bayer AG
• Allergan
• AstraZeneca
• Kowa Company
• Dicerna Pharmaceuticals
• Arrowhead Pharmaceuticals
Recent Development in the Cardiometabolic Disease Market
• Amgen: Amgen launched Repatha, a PCSK9 inhibitor, targeting reduction in LDL cholesterol levels to prevent cardiovascular events. The initiative focuses on improving outcomes for patients at risk of cardiovascular diseases through innovative therapies.
• Bayer: Bayer introduced a digital health platform aimed at enhancing diabetes and cardiovascular disease management. The platform integrates patient data, analytics, and personalized care plans to improve treatment adherence and outcomes.
• Sinopharm: Sinopharm initiated clinical trials for a novel insulin therapy designed to improve glycemic control in diabetes patients. The initiative aims to address the growing prevalence of diabetes in China and enhance treatment options available to patients.
• Dr. ReddyÄX%$%Xs Laboratories: Dr. ReddyÄX%$%Xs Laboratories launched a generic version of a widely used cardiovascular medication, aiming to increase affordability and accessibility of essential treatments for patients globally. The initiative supports efforts to manage and control cardiometabolic diseases more effectively.
Features of the Global Cardiometabolic Disease Market
Market Size Estimates: Cardiometabolic disease market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Cardiometabolic disease market size by various segments, such as type, treatment, end use, distribution channel, and region in terms of value ($B).
Regional Analysis: Cardiometabolic disease market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, treatments, end uses, distribution channels, and regions for the cardiometabolic disease market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cardiometabolic disease market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for cardiometabolic disease market?
Answer: The global cardiometabolic disease market is expected to grow with a CAGR of 6.1% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the cardiometabolic disease market?
Answer: The major drivers for this market are global increase in the prevalence of cardiometabolic diseases such as diabetes, hypertension, dyslipidemia, and obesity, advancements in medical technology and therapeutics, and rising healthcare expenditure, particularly in developed and emerging markets.
Q3. What are the major segments for cardiometabolic disease market?
Answer: The future of the cardiometabolic disease market looks promising with opportunities in the clinic and hospital markets.
Q4. Who are the key cardiometabolic disease market companies?
Answer: Some of the key cardiometabolic disease companies are as follows:
• Cardax
• Novartis AG
• Novo Nordisk A/S
• Eli Lilly and Company
• Bayer AG
• Allergan
• AstraZeneca
• Kowa Company
• Dicerna Pharmaceuticals
• Arrowhead Pharmaceuticals
Q5. Which cardiometabolic disease market segment will be the largest in future?
Answer: Lucintel forecasts that chronic/congestive heart failure is expected to witness the highest growth over the forecast period.
Q6. In cardiometabolic disease market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the cardiometabolic disease market by type (chronic/congestive heart failure, hypertension, type 2 diabetes, and obesity), treatment (ACE inhibitors, diuretics, glucophage, liposuction, and others), end use (clinics, hospitals, and others), distribution channel (hospital pharmacy, retail pharmacy, and online pharmacy), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Cardiometabolic Disease Market Market, Cardiometabolic Disease Market Market Size, Cardiometabolic Disease Market Market Growth, Cardiometabolic Disease Market Market Analysis, Cardiometabolic Disease Market Market Report, Cardiometabolic Disease Market Market Share, Cardiometabolic Disease Market Market Trends, Cardiometabolic Disease Market Market Forecast, Cardiometabolic Disease Market Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.